Global media also writes on failure of cloud-seeding in Delhi and the increasing demand for weight-loss drugs. FT interviews Sumant Sinha, founder of ReNew Energy.
Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and Wegovy, are expiring in nearly 100 nations.
India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.
Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.
Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity.
India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to transform access to weight-loss treatment.
Electoral competition now appears dominated by welfare delivery and governance metrics, but ideology has not disappeared in Tamil Nadu. Instead, it has become strategic.
India’s fast-growing data centre sector may strain state electricity networks; Central Electricity Authority has urged Maharashtra, Andhra Pradesh, Telangana and Tamil Nadu to boost capacity.
On lessons from the ongoing West Asia conflict, he says that while US had superior technology and strike capability, Iran used geography to its advantage.
China patiently invested capital, skill and technology in coal gasification. Unlike it, we won’t move from words to action. As crude prices decline, we lose interest.
COMMENTS